CA Patent

CA2722084C — Carba-nucleoside analogs for antiviral treatment

Assigned to Gilead Sciences Inc · Expires 2016-08-23 · 10y expired

What this patent protects

Provided are imidazol [1,5-f] [1,2.4]triazinyl, imidazol [1,2,4]triazinyl, and [1,2,4] triazolo [4,3-f] [1,2,4] triazinyl nucleosides of formula I, nucleoside phosphates and prodrugs thereof, wherein X1 or X2 is independently C-R10 or N and wherein at least one of X1 and X2 is N.…

USPTO Abstract

Provided are imidazol [1,5-f] [1,2.4]triazinyl, imidazol [1,2,4]triazinyl, and [1,2,4] triazolo [4,3-f] [1,2,4] triazinyl nucleosides of formula I, nucleoside phosphates and prodrugs thereof, wherein X1 or X2 is independently C-R10 or N and wherein at least one of X1 and X2 is N. The compounds, compositions, and methods provided may be useful for the treatment of Flaviviridae virus infections, particularly hepatitis C infections. (see formula I)

Drugs covered by this patent

Patent Metadata

Patent number
CA2722084C
Jurisdiction
CA
Classification
—
Expires
2016-08-23
Drug substance claim
No
Drug product claim
No
Assignee
Gilead Sciences Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.